Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reporting results for deep molecular responses in chronic myeloid leukemia

Leukemia volume 30, pages 1630–1631 (2016)Cite this article

Subjects

The recent recommendations of the European Treatment and Outcome Study (EUTOS) for chronic myeloid leukemia (CML) aim to standardise the reporting of molecular response (MR) as quantified by RT-quantitative polymerase chain reaction (qPCR).1 This is becoming an important issue as treatment is producing very low levels of disease in an increasing number of patients, and decisions on whether to cease or continue treatment are becoming increasingly common.

The EUTOS recommendations will be very useful as guidelines for testing laboratories, but several points need further discussion

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999–1003.

    Article  CAS  Google Scholar 

  2. Ho-Wan IP, Chi-Chiu SO . Deep molecular response in chronic myelogenous leukemia: ensuring accuracy and consistency. Leukemia 2015; 29: 1620–1621.

    Article  Google Scholar 

  3. Latham S, Bartley PA, Budgen B, Ross DM, Hughes E, Branford S et al. BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. J Clin Pathol 2016; e-pub ahead of print 2 February 2016 doi:10.1136/jclinpath-2015-203538.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology and Genetic Pathology, Flinders University and Medical Centre, Adelaide, South Australia, Australia

    A A Morley

Authors
  1. A A Morley
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to A A Morley.

Ethics declarations

Competing interests

The author holds equity in Monoquant Pty Ltd, which holds a patent related to sequencing of BCR-ABL1.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morley, A. Reporting results for deep molecular responses in chronic myeloid leukemia. Leukemia 30, 1630–1631 (2016). https://doi.org/10.1038/leu.2016.94

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/leu.2016.94

This article is cited by

Search

Advanced search

Quick links